The research group of Dr Francesco Saverio Tedesco from the UCL department of Cell and Developmental Biology is conducting the research, which is being supported through funding of
Furiex Pharmaceuticals, under its agreement with Takeda, is eligible to receive royalties and sales-based milestones if trelagliptin succinate is approved and marketed in Japan. Takeda Pharmaceutical has submitted
Polycythemia vera a chronic, incurable blood cancer associated with an overproduction of blood cells. Novartis announced that the Phase III study of Jakavi has met its primary endpoint
The FDA approval will allow the company to start its US based Phase III study in adult patients with ADHD, and patient enrollment is expected to start shortly.
TrialCTA is a cloud-based Software-as-a-Service (SaaS) application that helps Clinical Research Organizations (CRO’s), medical device and pharmaceutical companies manage and track the complex, global clinical trial contracts related
At the new GMP manufacturing facility, the company has implemented its proprietary, fully automated 3D cell expansion manufacturing platform that uses its patented high-throughput culturing technologies, 3D bioreactors,
Hypogonadism (commonly known as Low-T) is related with a deficiency or absence of the male hormone testosterone. The medicine is indicated to produce serum testosterone levels in the
The patent, entitled ‘Single-Walled Carbon Nanotube/Sirna Complexes And Methods Related Thereto’, will extend the intellectual property coverage of Ensysce and add to the extensive package of patents for
Sirturo is indicated when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. The approval follows a positive opinion from the Committee for
The preclinical Focal Adhesion Kinase (FAK) inhibitors originate from the Australian Cancer Therapeutics CRC (CTx). According to the companies the two licenses include fees, milestones and royalty payments.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.